Study Says Combined Drugs Can Shrink Tumour By 60 Percent In Bowel Cancer

Updated Jul 25, 2024 | 06:09 PM IST

SummaryA new study has found that combining the use of botanciiimab and balstilumab can reduce tumours caused by bowel cancer by 60%, marking the first time a durable response to immunotherapy has been reported in patients suffering from this condition.
close-up-medicine-containers-table

A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

End of Article

Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Updated Nov 19, 2026 | 09:11 AM IST

SummaryEli Lilly's GLP-1 pill Foundayo will be available for purchase in Canada from January 2027. Health Canada's approval comes just as a recent study observed GLP-1 drugs beat metformin in diabetes prevention.
Canada Approves Daily GLP-1 Pill As New Study Finds Drugs May Outperform Metformin In Diabetes Management

Credit: AI

Canada's regulatory body Health Canada recently approved GLP-1 pill developed by pharmaceutical company Eli Lilly. The weight loss pill offers an alternative to injectable weight-loss and diabetes medications.

The development comes as new study suggests that GLP-1 drugs could be more effective than metformin in preventing Type 2 diabetes and improving blood sugar in people with obesity and prediabetes.

The newly approved drug, Foundayo (orforglipron) is approved for adults with obesity and have at least one related health condition. It is also approved to help manage Type 2 diabetes.

Unlike popular GLP-1 medications like Ozempic and Wegovy, which are administered through injections, Foundayo is taken orally once a day. The company expects the GLP-1 pill to become available in Canadian pharmacies in January 2027.

How Does Foundayo Work?

Also read: Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1 (GLP-1), which is naturally-occurring hormone released by the gut after eating.

GLP-1 helps regulate blood sugar by stimulating insulin release when glucose levels increase. It also suppresses glucagon, a hormone that raises blood sugar, slows emptying of stomach and targets areas of the brain responsible for appetite. These effects, together, help improve blood sugar control, reduce hunger and support weight loss.

Unlike peptide-based GLP-1 medicines, orforglipron is a small molecule that can be absorbed orally without being broken down by digestive enzymes. It can also be taken without the food and water restrictions that come with some oral GLP-1 medications.

Novo Nordisk’s Rybelsus is already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.

Can GLP-1 Drugs Outperform Metformin?

Also read: New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?

A separate study presented at the American Heart Association's Scientific Sessions 2026 compared GLP-1 medications to metformin in more than 256,000 adults with obesity and prediabetes.

Researchers found that people taking GLP-1 medications were 1.5 times more likely to return to normal blood sugar levels than those taking metformin. They also had a 31% lower risk of developing Type 2 diabetes and a 41% lower risk of death from any cause. GLP-1 users were also at lower risks of heart attacks, strokes and heart failure events.

But the study analysed health records rather than conducting a randomised clinical trial. It also grouped several GLP-1 medicines together, including semaglutide, tirzepatide, liraglutide and dulaglutide. Orforglipron was not among the drugs evaluated.

Study author Vinicius de Sousa Barzon Serra said, "Metformin is still a first-line treatment choice. It is safe, inexpensive and has a long track record. This is less about replacing one medication with another and more about discussing additional options with specific patients."

Side Effects Of GLP-1 Medications

Common side effects of GLP-1 medications include gastrointestinal effects like nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These symptoms are often more noticeable when treatment begins or doses increase.

Although oral medicines offer an alternative to injections, they are not suitable for everyone. It depend on a person's medical history, blood sugar levels, weight and other health conditions.

End of Article

Pennsylvania's Eighth Measles Death Takes US Toll To 11 As Cases Cross 5,700: Who Needs A Booster Shot?

Updated Nov 19, 2026 | 08:19 AM IST

SummaryPennsylvania recently reported its eighth measles-associated death after an individual from Clinton County, who had tested positive for the disease, died. This takes the national measles death toll to 11 as cases cross 5,700.
Pennsylvania's Eighth Measles Death Takes US Toll To 11 As Cases Cross 5,700: Who Needs A Booster Shot?

Credit: AI image

Pennsylvania has reported its eighth measles-associated death of 2026 as the US battles a major outbreak that cost it its measles elimination status.

The news came a day after the Pan American Health Organization (PAHO) announced that the US, Mexico, and Bolivia had lost their measles elimination status. The US had maintained their measles-free status since 2000.

Pennsylvania has recorded around 1,589 confirmed cases across 46 counties, prompting authorities to urge people to check their vaccination status and ensure they are adequately protected. The total number of cases in the US has crossed more than 5,700.

The latest death, confirmed on November 18, involved an unvaccinated resident of Clinton County who had tested positive for measles. Health authorities have not disclosed the individual's age or other relevant details. According to the Pennsylvania Department of Health, the state has also reported 315 hospitalisations linked to the outbreak.

With measles cases spreading everyday, questions about whether adults who received measles vaccines during childhood need another dose have emerged. Health experts believe that most people who have received the recommended two doses of the measles, mumps and rubella (MMR) vaccine do not need a booster.

Who Needs A Booster Measles Vaccine Dose?

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

According to the US Centers for Disease Control and Prevention (CDC), adults born in 1957 or later who do not have evidence of immunity should receive at least one dose of the MMR vaccine. But certain groups are recommended to receive two doses, separated by at least 28 days. These include:

  • Healthcare workers: Those who are exposed to infected patients and could transmit the virus to vulnerable individuals.
  • International travellers: People travelling to countries where measles transmission is occurring.
  • College and university students: Students who may be exposed in crowded environments.
  • People living with immunocompromised individuals: Close contacts of people with weakened immune systems who may be unable to receive live vaccines themselves.
  • People living with HIV: Those who do not have severe immunosuppression and lack of measles immunity.
  • People in outbreak-affected areas: Adults advised to receive a second dose because of increased exposure.

People who have received two documented doses of the MMR vaccine, with the first administered at or after 12 months of age and the doses appropriately spaced, are considered protected for life.

Adults Born Before 1957 Are Considered Immune

Also read: Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond

According to the CDC, adults born before 1957 are presumed to have immunity against measles because the virus circulated widely before the vaccine became available in 1963.

However, healthcare workers born before 1957 who do not have a history of previous measles infection should consider receiving two doses of the MMR vaccine.

People vaccinated between 1963 and 1967 with the older inactivated (killed) measles vaccine may also need another dose. This version was later found to be ineffective.

Who Should Avoid The MMR Vaccine?

The MMR vaccine is a live attenuated vaccine, which means it contains weakened forms of the viruses.

Pregnant women and people with severe immune suppression should generally not receive it. Individuals with a history of severe allergic reactions to a previous dose or vaccine component should also seek medical advice.

People who are unsure about their vaccination history, immune status or need for another dose should consult their healthcare provider.

Measles Resurgence In The US

Measles is one of the most contagious infectious diseases. The virus spreads through respiratory droplets and airborne particles. They can remain active in the air for up to two hours after an infected person leaves an area.

Symptoms typically start with fever, cough, runny nose and red, watery eyes, followed by a rash that usually starts on the face and spreads across the body.

Complications can include pneumonia, brain inflammation (encephalitis), permanent disability and death. Infants, young children and people with weakened immune systems are vulnerable. The resurgence has been attributed to declining vaccination coverage.

End of Article

US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Updated Nov 19, 2026 | 01:00 AM IST

SummaryThe CDC has reported elevated rhinovirus/enterovirus and respiratory adenovirus activity across the US, with adenovirus increasing in some regions. It has also flagged Group A strep, whooping cough and walking pneumonia.
US Respiratory Viruses In 2026: CDC Identifies 4 Illnesses To Watch

Credit: iStock

The US Centers for Disease Control and Prevention (CDC) has reported elevated activity of multiple respiratory viruses across the country during the 2026–27 winter season, including rhinovirus/enterovirus and respiratory adenovirus.

While respiratory adenovirus infections are increasing in some regions, the agency says the trends are expected.

In its latest update, the CDC also highlighted Group A strep infections, whooping cough and Mycoplasma pneumoniae, the bacteria responsible for walking pneumonia, as other respiratory illnesses circulating in the US.

Rhinovirus, Adenovirus

Rhinovirus/enterovirus and respiratory adenovirus activity are elevated nationally, according to the CDC. Respiratory adenovirus infections are also increasing in some parts of the country.

Both viruses can cause respiratory symptoms such as cough, fever, nasal congestion and shortness of breath. In severe cases, infections may progress to bronchitis or pneumonia.

Rhinoviruses are among the common causes of the common cold and can also trigger asthma attacks. People with asthma, weakened immune systems or other underlying medical conditions may be at higher risk of severe illness.

Respiratory adenoviruses typically cause mild cold- or flu-like symptoms but can also lead to bronchitis, pneumonia, conjunctivitis (pink eye) and gastrointestinal illness. People with weakened immune systems or existing respiratory or cardiac conditions are at greater risk of severe disease. There are no vaccines available to the public for these infections.

Group A Strep Infections

Reports of Group A strep infections increased in the US as children returned to school this fall, before stabilising, the CDC said.

Most reported infections have involved strep throat or scarlet fever.

However, the bacteria can also cause serious conditions, including streptococcal toxic shock syndrome and necrotising fasciitis, commonly known as flesh-eating disease.

Although most infections are minor, serious illness can occur, particularly among older adults and people with certain underlying health conditions. Healthcare providers can diagnose the infection through testing and prescribe antibiotics when needed.

Walking Pneumonia

Respiratory infections caused by Mycoplasma pneumoniae remain low in most parts of the US, based on emergency department visits and positive test results.

The bacteria commonly cause tracheobronchitis, often described as chest colds, but can also lead to walking pneumonia. People of all ages can get infected, although school-aged children and young adults are most commonly affected.

Most mild infections resolve without medication, while healthcare providers may prescribe antibiotics for pneumonia.

Whooping Cough

Whooping cough, or pertussis, continues to circulate at lower levels compared with post-pandemic peaks, according to the CDC.

The highly contagious respiratory infection is caused by the bacterium Bordetella pertussis and can spread easily from person to person.

Babies younger than one year are at the highest risk of severe disease and complications. Vaccination is the best way to prevent complications, and healthcare providers generally treat the infection with antibiotics.

How To Prevent Respiratory Infections

The CDC recommends basic precautions to reduce the spread of respiratory viruses and bacteria, including:

  • Washing hands regularly
  • Cleaning frequently touched surfaces
  • Covering coughs and sneezes
  • Staying home when sick
  • Taking steps to improve indoor air quality.
People with respiratory symptoms such as fever, cough or shortness of breath should take precautions to avoid spreading infections to others. Severe symptoms, particularly difficulty breathing, warrant medical attention.

End of Article